Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Reed, Nicholas S
NCT04524442 / 2019-004073-76: Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients	Completed	4	42	Europe	arginine/lysine, LysaKare	Advanced Accelerator Applications	Gastroenteropancreatic Neuroendocrine Tumors	11/23	11/23
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26